Novartis announces changes to the Executive Committee to support strategic priorities

Novartis International AG / Novartis announces changes to the Executive Committee to support strategic priorities . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.

• Bertrand Bodson, Chief Digital Officer, appointed to the Executive Committee of Novartis (ECN)
   

Steffen Lang, Global Head Novartis Technical Operations, appointed to the ECN
 

Shannon Klinger named Chief Ethics, Risk and Compliance Officer, appointed to the ECN
 

André Wyss, President Novartis Operations and Country President for Switzerland, decided to leave Novartis

Basel, March 12, 2018 - Novartis announced today changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global Head Novartis Technical Operations, and Shannon Klinger, Chief Ethics, Risk and Compliance Officer, have been appointed to the Executive Committee of Novartis (ECN). All changes are effective as of April 1, 2018. André Wyss, President Novartis Operations, has decided to step down from the ECN on April 1, 2018, to pursue his career outside of Novartis.

Vas Narasimhan, CEO of Novartis, said: "We are making these changes to harness the full strength of Novartis as we build the leading medicines company, powered by data and digital. The appointments of Bertrand Bodson, Steffen Lang and Shannon Klinger to the ECN will help us accelerate our efforts to lead in data and digital, increase our focus on operational execution, and reinforce our commitment to return more to society than we take."

"André Wyss has decided to leave Novartis so he can start a new chapter in his career. His journey is unique: he has grown from a chemistry apprentice in manufacturing all the way to the Executive Committee as the President of Novartis Operations and Country President for Switzerland. I want to thank André for his leadership, his loyalty to our company as well as his significant contributions and business impact he had over the past three decades," said Dr. Narasimhan.